The Role of an Aggrecan 32mer Fragment in Post-Traumatic Osteoarthritis
Technical Report,30 Sep 2017,29 Sep 2018
University of Melbourne Parkville Australia
Pagination or Media Count:
Recommended to be brief approx. 200 words of the main findings during the reporting period. In this second reporting period, we achieved three major milestones 1. We finalized the histological analysis of all knees of the prophylactic experiment performed in year 1. We found no effect of a 10-week prophylactic treatment with AF 28 on cartilage damage or proteoglycan loss. Analyses of bone damage are in progress. 2. We completed a 16-week experiment where mice were treated starting 2 weeks after DMM surgery. This treatment strategy had no effect on pain-related behaviors. 3. We successfully developed an assay to measure the 32-mer fragment in human serum, which has great potential as a novel biomarker for OAOA pain, as well as a target marker for aggrecanase activity. Unfortunately, we have also encountered issues that delayed progress and will require substantive changes going forward 1. The data collected to date suggest that AF-28 is not a neutralizing antibody. Further in vivo experiments are on hold until analysis of the first DMM experiment is complete. 2. PI Fosang has a health issue and we therefore, urgently requested that co-I Malfait can share the role of Co-PI.
- Medicine and Medical Research